Amgen stock after-hours at EUR 366.23: minus 1.35 percent versus Lang & Schwarz prior close
Published on 10/01/2026 at 20:59 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Amgen stock was at EUR 366.23 in after-hours trading at 8:51 p.m. CEST on October 1, 2026, down 1.35 percent versus the EUR 371.25 prior close at Lang & Schwarz.
Amgen stock in after-hours trading
The Lang & Schwarz quote showed a bid of EUR 365.85 and an ask of EUR 366.60. The further course of after-hours trading at Lang & Schwarz until 11:00 p.m. CEST is shown by the continuously updated real-time quote of Amgen stock.
Dazodalibep reaches Phase 3 endpoint
In a release dated September 22, 2026, Amgen said its Phase 3 OASIZ 301 study of investigational dazodalibep met its primary endpoint in adults with Sjögren's disease and moderate-to-severe systemic disease activity. The company reported statistically significant and clinically meaningful improvement at Week 48 on the EULAR Sjögren's Syndrome Disease Activity Index, with improvements observed as early as Week 4 and sustained through Week 48.
Amgen said the most common adverse events were generally mild to moderate, while discontinuations due to adverse events were low and balanced across treatment groups. The company plans to present detailed OASIZ 301 data at an upcoming medical meeting and expects its separate Phase 3 OASIZ 303 study to complete in the fourth quarter of 2026.
